For renal clear cell carcinoma, CPT2 was able to promote the malignant biological behavior of cells, as well as increase sorafenib resistance by inhibiting FAO and decreasing NADPH (nicotinamide adenine dinucleotide phosphate), thereby activating the ROS/PPARγ/NF-κB pathway [127]. This evidence concerns the gene CPT2 and clear cell renal carcinoma.